



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



## QuickStripe™ Chlamydia Ag

A rapid test for the qualitative detection of *Chlamydia antigen* in female cervical swab, male urethral swab and male urine specimens.

### Instruction Manual

Test kit for 20 tests individually pouched  
(Catalog No. 41101)

For *In Vitro* Diagnostic Use

For professional use

Store at 2-30°C. **Do Not Freeze**



**Savyon® Diagnostics Ltd.**

3 Habosem St. Ashdod 7761003  
ISRAEL

Tel.: +972.8.8562920

Fax: +972.8.8523176

E-mail:

[support@savyondiagnosics.com](mailto:support@savyondiagnosics.com)

### Intended Use

The *QuickStripe™* Chlamydia Ag is a rapid chromatographic immunoassay for the qualitative detection of *Chlamydia trachomatis* in female cervical swab, male urethral swab and male urine specimens to aid in the diagnosis of Chlamydia infection.

### Summary

*Chlamydia trachomatis* is the most common cause of sexually transmitted venereal infection in the world. It is composed of elementary bodies (the infectious form) and reticulate or inclusions bodies (the replicating form). *Chlamydia trachomatis* has both a high prevalence and asymptomatic carriage rate, with frequent serious complications in both women and neonates. Complications of Chlamydia infection in women include cervicitis, urethritis, endometritis, pelvic inflammatory disease (PID) and increased incidence of ectopic pregnancy and infertility.<sup>1</sup> Vertical transmission of the disease during parturition from mother to neonate can result in inclusion conjunctivitis pneumonia. In men, complications of Chlamydia infection include urethritis and epididymitis. At least 40% of the nongonococcal urethritis cases are associated with Chlamydia infection. Approximately 70% of women with endocervical infections and up to 50% of men with urethral infections are asymptomatic. Traditionally, Chlamydia infection has been diagnosed by detection of Chlamydia inclusions in tissue culture cells. Culture method is the most sensitive and specific laboratory method, but it is labor intensive, expensive, long (48-72 hours) and not routinely available in most institutions. The *QuickStripe™* Chlamydia Ag is a rapid test to qualitatively detect the Chlamydia antigen from female cervical swab, male urethral swab and male urine specimens, providing results in 10 minutes. The test utilizes antibody specific for Chlamydia to selectively detect Chlamydia antigen from female cervical

swab, male urethral swab and male urine specimens.

### Principle

The *QuickStripe™* Chlamydia Ag is a qualitative, lateral flow immunoassay for the detection of Chlamydia antigen from female cervical swab, male urethral swab and male urine specimens.

In this test, antibody specific to the Chlamydia antigen is coated on the test line region of the test. During testing, the extracted antigen solution reacts with an antibody to Chlamydia that is coated onto particles. The mixture migrates up to react with the antibody to Chlamydia on the membrane and generates a colored line in the test line region. The presence of this colored line in the test line region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a colored line will always appear in the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

### Reagents

The test device contains Chlamydia antibody coated particles and Chlamydia antigen coated on the membrane.

### Precautions

- For professional *in vitro* diagnostic use only. Do not use after expiration date.
- The test device should remain in the sealed pouch until use.
- Do not eat, drink or smoke in the area where the specimens or kits are handled.
- Do not use test if pouch is damaged.
- Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow standard procedures for proper disposal of specimens.
- Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested.
- Humidity and temperature can adversely affect results.
- Use only **sterile** swabs to obtain endocervical specimens.

### Storage and Stability

Store as packaged in the sealed pouch either at room temperature or refrigerated (2-30°C). The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

### Specimen Collection and Preparation

- The *QuickStripe™* Chlamydia Ag can be performed using female cervical swab, male urethral swab and male urine specimens.
- The quality of specimens obtained is of extreme importance. Detection of Chlamydia requires a vigorous and thorough collection technique that provides cellular material rather than just body fluids.
- To collect **Female Cervical Swab Specimens:**
  - Use the swab provided in the kit.
  - Before specimen collection, remove excess mucus from the endocervical area with a cotton ball and discard. The swab should be inserted into the endocervical canal, past the squamocolumnar junction until most of the tip is no longer

visible. This will permit acquisition of columnar or cubical epithelial cells, which are the main reservoir of the Chlamydia organism. Firmly rotate the swab 360° in one direction (clockwise or counterclockwise), let stand for 15 seconds, then withdraw the swab. Avoid contamination from exocervical or vaginal cells. Do **not** use 0.9% sodium chloride to treat swabs before collecting samples.

- If the test is to be conducted immediately, put the swab into the extraction tube.

- To collect **Male Urethral Swab Specimens:**

- Standard plastic- or wire-shaft sterile Dacron swabs should be used for urethral specimen collection. Instruct patients not to urinate for at least one hour prior to specimen collection.

- Insert the swab into the urethra about 2-4 cm, rotate the swab 360° in one direction (clockwise or counterclockwise), let stand for 10 seconds, then withdraw. Do **not** use 0.9% sodium chloride to treat swabs before collecting samples.

- If the test is to be conducted immediately, put the swab into the extraction tube.

- To collect **Male Urine Specimens:**

- Collect 15-30 mL of clean first morning urine in a sterile urine cup. First morning urine specimens are preferred to achieve the highest concentrations of Chlamydia antigen.

- Mix the urine specimen by inverting the container. Transfer 10 mL of the urine specimen into a centrifuge tube, add 10 mL distilled water and centrifuge at 3,000 rpm for 15 minutes.

- Carefully discard the supernatant, keep the tube inverted and remove any supernatant from the rim of tube by blotting onto absorbent paper.

- If the test is to be conducted immediately, treat the urine pellet according to the Directions for Use.

- It is recommended that specimens be processed as soon as possible after collection. If immediate testing is not possible, the patient swab specimens should be placed in a dry transport tube for storage or transport. The swabs may be stored for 4-6 hours at room temperature (15-30°C) or 24-72 hours refrigerated (2-8°C). The urine specimens can be stored refrigerated (2-8°C) for 24 hours. Do not freeze. All specimens must be allowed to reach room temperature (15-30°C) before testing.

### Materials Required But Not Provided

- Timer
- Centrifuge tube (for male urine specimens only)
- Positive control
- Negative control
- Urine cup (for male urine specimens only)
- Sterile male urethral swabs

### Directions for Use

**Allow the test device, specimen, reagents, and/or controls to reach room temperature (15-30°C) prior to testing.**

1. Remove the test device from the sealed foil pouch and use it as soon as possible. Best results will be obtained if the test is performed immediately after opening the foil pouch.
2. Extract the Chlamydia antigen according to the specimen type.

### For Female Cervical or Male Urethral Swab Specimens:



- Hold the Reagent A bottle vertically and **add 5 full drops of Reagent A** (approximately 300 µL) to the extraction tube. Reagent A is colorless. Immediately insert the swab, compress the bottom of the tube and rotate the swab 15 times. Let stand for 2 minutes.
- Fill the quantitative pipette for Reagent B up to the marked line (approximately 220 µL) then **add the Reagent B** to the extraction tube. The solution will turn cloudy. Compress the bottom of tube and **rotate the swab 15 times** until the solution turns to a clear color with a slight green or blue tint. If the swab is bloody, the color will turn yellow or brown. Let stand for 1 minute.
- Press the swab against the side of the tube and withdraw the swab while squeezing the tube. Keep as much liquid in the tube as possible. Fit the dropper tip on top of the extraction tube.


### For Male Urine Specimens:

- Fill the quantitative pipette for **Reagent B** to the marked line (approximately 220 µL) then **add the Reagent B** to the urine pellet in the centrifuge tube, then draw the liquid up and down with a pipette to vigorously mix until the suspension is homogeneous.
  - Transfer all the solution in the centrifuge tube to an extraction tube. **Let stand for 1 minute.** Hold the **Reagent A** bottle upright and **add 5 full drops of Reagent A** (approximately 300 µL) then add to the extraction tube. Vortex or tap the bottom of the tube to mix the solution. **Let stand for 2 minutes.**
  - Fit the dropper tip on top of the extraction tube.
3. Place the test device on a clean and level surface. **Add 3 full drops of the extracted solution** (approximately 100µL) to the specimen well (S) of the test device, and start the timer. Avoid trapping air bubbles in the specimen well (S).
  4. Wait for the colored line(s) to appear. **Read results at 10 minutes.** If no line appears after 10 minutes, please read again at 20 minutes. Even a faint colored line should be considered as positive.

### Materials

#### Materials Provided

|   |   |  |
|---|---|--|
| <ul style="list-style-type: none"> <li>• Test devices</li> <li>• Sterile female cervical swabs</li> <li>• Package insert</li> </ul> | <ul style="list-style-type: none"> <li>• Test tubes</li> <li>• Workstation</li> </ul> | <ul style="list-style-type: none"> <li>• Dropper tips</li> <li>• Quantitative pipette</li> </ul>   |
| Reagent A (0.2M NaOH)   |    | R36/38 Irritating to eyes and skin. (S2 Keep out of the reach of children.) (S46 If swallowed, seek medical advice immediately and show this container or label.) S60 This material and its container must be disposed of as hazardous waste.                          |
| Reagent B (0.2N HCl)  |    | R35 Causes severe burns. S1/2 Keep locked up and out of reach of children. S45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). S60 This material and its container must be disposed of as hazardous waste. |



**Expected Values**

For women attending STD clinics and other high-risk populations, the prevalence of Chlamydia infection has been reported to be between 20% and 30%. In a low-risk population such as those patients attending obstetrics and gynecology clinics, the prevalence is approximately 5% or less. Reports show that for men attending STD clinics, the prevalence of Chlamydia infection is approximately 8% in asymptomatic men and 11% in symptomatic men.<sup>1,2</sup> Normal carriage rates of Chlamydia in asymptomatic men are less than 5%.<sup>3</sup>

**Interpretation of Results**

(Please refer to the illustration above)

**POSITIVE:**\* **Two distinct colored lines appear.** One line should be in the control line region (C) and another line should be in the test line region (T).

**\*NOTE:** The shade of color in the test line region (T) may vary, but it should be considered positive whenever there is even a faint colored line.

**NEGATIVE:** **One colored line appears in the control line region (C).** No apparent colored line appears in the test line region (T).

**INVALID: Control line fails to appear.** Insufficient sample volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

**Quality Control**

**A procedural control is included in the test. A colored line appearing in the control line region (C) is considered an internal procedural control.** It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

**Limitations**

1. The QuickStripe™ *Chlamydia Ag* is for *in vitro* diagnostic use only. This test should be used for the detection of Chlamydia antigen from female cervical swab, male urethral swab and male urine specimens. Neither the quantitative value nor the rate of increase in Chlamydia antigen concentration can be determined by this qualitative test.
2. This test will only indicate the presence of Chlamydia antigen in specimens from both viable and non-viable Chlamydiae. Performance with other specimens has not been assessed.
3. Detection of Chlamydia is dependent on the number of organisms present in the specimen. This can be affected by specimen collection methods and patient factors such as age, history of Sexually Transmitted Diseases (STDs), presence of symptoms, etc. The minimum detection level of this test may vary according to serovar. Therefore, the test results should be interpreted in conjunction with other laboratory and clinical data available to the physician.
4. Therapeutic failure or success cannot be determined as antigen may persist following appropriate antimicrobial therapy.
5. Excessive blood on the swab may cause false positive results.

**Performance Characteristics**

**Sensitivity**

The QuickStripe™ *Chlamydia Ag* has been evaluated with specimens obtained from patients of STD clinics. PCR is used as the reference method for QuickStripe™ *Chlamydia Ag*. Specimens were considered positive if PCR indicated a positive result. Specimens were considered negative if PCR indicated a negative result. The results show that QuickStripe™ *Chlamydia Ag* has a high sensitivity relative to PCR.

**Specificity**

The QuickStripe™ *Chlamydia Ag* uses an antibody that is highly specific for Chlamydia antigen in female cervical swab, male urethral swab and male urine specimens. The results show that the QuickStripe™ *Chlamydia Ag* has a high specificity relative to PCR.

For **Female Cervical Swab Specimens:**

| Method                   | PCR      |          | Total Results |          |
|--------------------------|----------|----------|---------------|----------|
|                          | Results  | Positive |               | Negative |
| QuickStripe Chlamydia Ag | Positive | 46       | 3             | 49       |
|                          | Negative | 6        | 87            | 93       |
| <b>Total Results</b>     |          | 52       | 90            | 142      |

Relative Sensitivity: 88.5% (76.6%-95.6%)\*

Relative Specificity: 96.7% (90.6%-99.3%)\*

Accuracy: 93.7% (88.3%-97.1%)\*

\* 95% Confidence Interval

For **Male Urethral Swab Specimens:**

| Method                   | PCR      |          | Total Results |          |
|--------------------------|----------|----------|---------------|----------|
|                          | Results  | Positive |               | Negative |
| QuickStripe Chlamydia Ag | Positive | 40       | 8             | 48       |
|                          | Negative | 11       | 104           | 115      |
| <b>Total Results</b>     |          | 51       | 112           | 163      |

Relative Sensitivity: 78.4% (64.7%-88.7%)\*

Relative Specificity: 92.9% (86.4%-96.9%)\*

Accuracy: 88.3% (82.4%-92.8%)\*

\* 95% Confidence Interval

For **Male Urine Specimens:**

| Method                         |          | PCR      |          | Total Results |
|--------------------------------|----------|----------|----------|---------------|
| QuickStripe<br>Chlamydia<br>Ag | Results  | Positive | Negative |               |
|                                | Positive | 20       | 0        | 20            |
|                                | Negative | 2        | 35       | 37            |
| <b>Total Results</b>           |          | 22       | 35       | 57            |

Relative Sensitivity: 90.9% (70.8%-98.9%)\*

Relative Specificity: >99.0% (90.0%-100.0%)\*

Accuracy: 96.5% (87.9%-99.6%)\*

\* 95% Confidence Interval

**Cross-Reactivity**

The antibody used in the QuickStripe™ *Chlamydia Ag* has been shown to detect all known *Chlamydia* serovars. *Chlamydia psittaci* and *Chlamydia pneumoniae* strains have not yet been tested with the QuickStripe™ *Chlamydia Ag*.

Cross reactivity with other organisms has been studied using suspensions of 10<sup>9</sup> Colony Forming Units (CFU)/mL. The following organisms were found negative when tested with the QuickStripe™ *Chlamydia Ag*:

|                                    |                                |                                   |
|------------------------------------|--------------------------------|-----------------------------------|
| <i>Acinetobacter calcoaceticus</i> | <i>Pseudomona aeruginosa</i>   | <i>Proteus mirabilis</i>          |
| <i>Acinetobacter spp</i>           | <i>Neisseria meningitides</i>  | <i>Neisseria gonorrhoea</i>       |
| <i>Enterococcus faecalis</i>       | <i>Salmonella choleraesuis</i> | Group B/C<br><i>Streptococcus</i> |
| <i>Enterococcus faecium</i>        | <i>Candida albicans</i>        | <i>Hemophilus influenzae</i>      |
| <i>Staphylococcus aureus</i>       | <i>Proteus vulgaris</i>        | <i>Branhamella catarrhalis</i>    |
| <i>Klebsiella pneumoniae</i>       | <i>Gardnerella vaginalis</i>   |                                   |

**Bibliography**

1. Sanders J.W. et al *Evaluation of an Enzyme Immunoassay for Detection of Chlamydia trachomatis in Urine of Asymptomatic Men*. J.Clinical Microbiology, 32,24-27, (1994).
2. Jaschek, G. et al *Direct Detection of Chlamydia trachomatis in Urine Specimens from Symptomatic and Asymptomatic Men by Using a Rapid Polymerase Chain Reaction Assay*. J. Clinical Microbiology, 31,1209-1212, (1993).
3. Schachter, J *Sexually transmitted Chlamydia trachomatis infection*. Postgraduate Medicine, 72, 60-69, (1982).